Home/Filings/4/0001839882-23-013975
4//SEC Filing

Desai Meera J. 4

Accession 0001839882-23-013975

CIK 0000887247other

Filed

May 29, 8:00 PM ET

Accepted

May 30, 6:15 PM ET

Size

5.4 KB

Accession

0001839882-23-013975

Insider Transaction Report

Form 4
Period: 2023-05-25
Transactions
  • Award

    Common Stock

    2023-05-25+3,1383,138 total
Footnotes (2)
  • [F1]On May 22, 2023, Adamis Pharmaceuticals Corporation ("Adamis") effected a 1 for 70 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
  • [F2]Received in exchange for common stock of DMK Pharmaceuticals Corporation, a privately held corporation ("DMK"), in connection with the merger of DMK into a subsidiary of Adamis (the "Merger"). On the effective date of the Merger, the closing price of Adamis common stock was $2.50 per share.

Issuer

Adamis Pharmaceuticals Corp

CIK 0000887247

Entity typeother

Related Parties

1
  • filerCIK 0001886559

Filing Metadata

Form type
4
Filed
May 29, 8:00 PM ET
Accepted
May 30, 6:15 PM ET
Size
5.4 KB